Du är här

2014-04-23

InvestmentPitch: Supreme Pharmaceuticals (CSE:SL) Lists on Canadian Securities Exchange - Video News Alert on Investmentpitch.com

Vancouver, BC, April 23, 2014 - Supreme Pharmaceuticals (CSE:SL) is one of the
latest new listings on the Canadian Securities Exchange, and is trading under
the symbol "SL". The company stated that its move from the TSX Venture
Exchange will allow it to efficiently and seamlessly transition from a junior
resource company to one whose main focus is now on the emerging medical
marijuana field.

InvestmentPitch.com has produced a "video news alert" which provides a brief
overview of the company. If this link is not enabled, please
visitwww.InvestmentPitch.comand enter "Supreme" in the search box.

President and CEO, David Stadnyk stated: "Our goal is to secure several
medical marijuana producing facilities, each
with a MMPR license. There is no assurance that we will be able to secure
such facilities. This is a critical year for MMPR licences and we plan on
making several applications to Health Canada. While we have longstanding
relationships with both the TSX Venture and the Canadian Securities Exchange,
we believe this is the right move for the Company at this time. We now have
two producing medical marijuana facilities under evaluation and expect to
report positive news shortly
."

The company has already signed a conditional agreement with an arms-length
South Okanagan-based company giving Supreme the option to purchase its
producing medical marijuana business.

The company, which until recently operated as Supreme Resources under the
symbol SPR, would appear to be better suited that most companies to make this
switch, as the current management team has a track record of finding and
developing early stage pharmaceutical or biomedical device companies. The
company also announced it has no plans to dispose of or shelve its mineral
exploration properties, and will continue to work on them as the
opportunities present themselves.

In September 2013, the company closed a private placement consisting of 79.9
million units $0.005, which contained a warrant to purchase a common share at
$0.05 for a period of 12 months. The recent increase in the share price has
facilitated the exercise of a significant number of these warrants, which
allowed the company to cancel its recently announced private placement.

The shares are trading at $0.055, and with 145 million shares outstanding, the
company is capitalized at $8 million.

For more information, please visit the company's
website,www.supremepharmaceuticals.comor contact David Stadnyk,
President&CEO, at 647-340-6744 or emailinfo@supremepharmaceuticals.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution
for creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing short three minute videos based on significant news releases and
research reports. Please visit InvestmentPitch.com and browse the extensive
library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InvestmentPitch via Globenewswire

HUG#1779283

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.